http://www.reportbuyer.com/rss.htmlHere you can find industry reports on Diabetes. Information includes Diabetic Complications, Insulin and Metabolic Syndrome. en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/world_amd_diabetic_retinopathy_pharmaceutical_market_2009_2024.htmlWith Increasing Retinal Disease Prevalence and Unmet Clinical Needs - Which Drug will be the Next Lucentis? The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. a1fc521dcf362065e4bf8c7f1b014c46Tue, 07 Jul 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/global_diabetes_market_1.htmlEmergence of Novel Drug Classes to Boost Market Growth Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change. e60ca6237d4f0af9ebcdcfa9d278f396Sat, 06 Jun 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/insulin_delivery_devices_market_analysis_future_forecast.htmlInsulin Delivery Devices Market Analysis and Future Forecast published by Renub Research gives a detailed analysis on the global insulin market. The report analyses and forecast on market size of different insulin delivery devices i. e. ffce08673cd984b1ee1ec855c211f9b2Sat, 06 Jun 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/toolkit_diabetes_msl_programs.htmlBuild a world-class diabetes medical science liaison (MSL) program Currently, about 246 million people worldwide have diabetes; this number is expected to increase to 380 million by 2025, according to the International Diabetes Foundation. Such staggering figures solidify diabetes' position as a primary therapeutic area. They also indicate the value of medical science liaisons who are building relationships within the diabetes medical community. 1239effd5af629f19abf412bee4fb0a5Tue, 05 May 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/blood_glucose_testing_diabetes_management.htmlThere has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. 0ba1d5835e66d311835fa13ec5510bffSat, 04 Apr 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/diabetes_metabolic_syndrome_cardiovascular_disease.htmlThere has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i. 3d58aad701cc14871ff558b18eef8519Sat, 04 Apr 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/future_diabetes_care_devices_market_2015.htmlGlobal Markets Direct’s “The Future of the Diabetes Care Devices Market to 2015” report provides key data, information and analysis on the global diabetes care devices market. The report provides market landscape, competitive landscape and market trends information on the glucose monitoring and insulin delivery market categories. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. c9cc4e16b0c2d2c43ec36634194f5605Mon, 30 Mar 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/world_diabetes_market_2007_2025.htmlAbout the Report The Renub Research report titled "The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market" gives a detailed analysis on the global diabetes market. This report investigates the top 10 countries: diabetes prevalence, diabetes drug market and insulin market. It also provides a description of the sales and market share of top 10 brands in anti-obesity drug and diabetes drug market globally. 47f2b7348afb586fca3ca10a7f71b9b0Tue, 03 Mar 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/world_diabetes_market_analysis_2009_2023.htmlIncidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. As discussed in this new visiongain report - World Diabetes Market Analysis, 2009-2023 - The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. 0009e28767f64af34e48070e65cd5b37Mon, 02 Feb 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/diabetes_drug_discoveries_2009_future_holds.htmlThis strategic report from Espicom puts the spotlight on current and future drugs that will be used in the treatment of Type I and Type II diabetes, providing industry and investors with a comprehensive overview of the market in the medium term. . e3431508b3e8ffa1e7eb6ee0910de85cMon, 02 Feb 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/china_diabetes_drug_market_report.htmlDiabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin, or alternatively, when the body cannot effectively use the insulin it produces. When China started its economic reform in 1978, the diabetes disease rate was about 0. 6% in the Chinese population. 2487b106119cd5ceb7aadd70f2e7c5f0Thu, 01 Jan 2009 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/opportunities_assessment_diabetes_therapeutics_south_korea.htmlThis research service aims to provide an update on the epidemiology of T2 diabetes, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the diabetes therapeutics market in South Korea. . 325c36d196b06b4fc3cfcbfe1c26629dFri, 12 Dec 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/opportunities_assessment_diabetes_therapeutics_australia.htmlThis research service aims to provide an update on the epidemiology of T2 diabetes, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the diabetes therapeutics market in Australia. . aae2350f616b6161de62b82b5924515fFri, 12 Dec 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/opportunities_assessment_diabetes_therapeutics_market_taiwan.htmlThis research service aims to provide an update on the epidemiology of T2 diabetes, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the diabetes therapeutics market in Taiwan. . e481cd09bf2a462edd87802d3a296617Fri, 12 Dec 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/strategic_analysis_south_african_hmi_markets.htmlThis research service examines the South African HMI market, providing detailed analysis and forecasts over the period 2004 to 2014. Revenue analyses are provided for each product type and end user market segment. In addition the key industry challenges, market drivers and restraints are discussed in terms of their impact of market developments over the forecast period. 2468f796357bfa1e489aeb1dc133fb86Fri, 12 Dec 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/european_diabetes_diagnostics_market.htmlSelf-monitoring and POC Diabetes Tests Offer Promise of Significant Growth The European diabetes diagnostics market is poised for expansion with segments such as self-monitoring and POC tests offering tremendous growth potential. Heightened efforts to generate awareness about diabetes and related diagnostic tests are a key driver in market development. For instance, limited awareness about HbA1C tests is restraining the laboratory market. c923b43d07e3d5242c80ffa17927955eFri, 12 Dec 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/emerging_diabetes_drugs.htmlProduct description The Competitive Intelligence Report Emerging Diabetes Drugs & Targets as of November 2008 provides a competitor analysis in the development pipeline of novel emerging antidiabetic treatment modalities for type 1 and 2 diabetes beyond the established targets PPAR agonists, DPP-IV inhibitors, GLP-1 receptor agonists and SGLT inhibitors. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets). 12005de19ac34e84bd346eb861bd09aeTue, 11 Nov 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/peroxisome_proliferator_activated_receptor_ppar_agonists.htmlProduct description The Competitive Intelligence Report Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as of November 2008 provides a competitor analysis in the development pipeline of novel PPAR alpha, gamma and delta agonists for treatment of dyslipidemia or type 2 diabetes or obesity. Peroxisome proliferator-activated receptors (PPARs) are members of a nuclear receptor superfamily which regulate gene expression and, thereby, controll energy metabolism. PPAR gamma has a key role in adipogenesis, insulin sensitivity, and glucose and lipid metabolism, and also plays a major role in vascular biology. 0911e5bcdde321fe9c907156c68e32f1Tue, 11 Nov 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/glp_1_receptor_agonists.htmlProduct description The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Analogs as of November 2008 provides a competitor analysis in the development pipeline of novel GLP-1 Analogs and GLP-1 receptor agonists for treatment of type 2 diabetes. Binding of glucagon-like peptide-1 (GLP-1) analogs or agonists to the GLP receptor induces insulin secretion from pancreatic beta cells. Exendin (Byetta) is the first representative of this new class of incretin mimetics, first approved in 2005 for treatment of type 2 diabetes. e3f517bb8668c7e71c5e53f3ccffa3a9Tue, 11 Nov 2008 12:00:00 GBDiseases/Diabeteshttp://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/stakeholder_opinions_diabetic_renal_disease.html Prevalence of diabetic renal disease is on the rise. Current treatment focuses on the management of hypertension and glycemic control, but is unable to address the deterioration of renal function. An unmet need exists for therapies fully reversing disease progression. 907ac93cfd44d22a8c25759c4a7a40d2Tue, 11 Nov 2008 12:00:00 GBDiseases/Diabetes